A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis

NCT ID: NCT04626921

Last Updated: 2023-12-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 55 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-10-22
• Study Completion Date: 2023-09-06

Brief Summary

Open-label, long-term extension study available to participants who have completed CNMAu8.201.

Detailed Description

This open-label, long-term extension study is only available to participants who have completed CNMAu8.201 (VISIONARY-MS). The Week 48/End-of-Study Visit for study CNMAu8.201 (VISIONARY-MS) will serve to establish the Baseline for electrophysiological, functional, morphological vision testing, as well as the neurological and outcome assessments. Participants will receive open-label CNM-Au8 throughout the study. All participants will receive a daily dose of 30 mg CNM-Au8 for the entire open-label, long-term extension study. The dose for participants may be adjusted once efficacy and safety data from study CNMAu8.201 becomes available, which may occur after participants have already started this study. Based upon a review of data and Sponsor or PI recommendation, this open-label, long-term extension study may be discontinued once each participant reaches her/his 48-week visit.

Conditions

Relapsing Multiple Sclerosis

Keywords

MS; RMS; Multiple Sclerosis; Demyelination; Remyelination; Optic Neuropathy; Optic Neuritis; Gold; Nanocrystal; Multifocal VEP; Full Field VEP; Low contrast letter acuity

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Active treatment with 30 mg of CNM-Au8

Highly pure elemental Au nanocrystals are suspended in deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) concentrated up to 0.5 mg/mL (500 ppm) Au.

Group Type: EXPERIMENTAL

CNM-Au8

Intervention Type: DRUG

30 mg of CNM-Au8

Interventions

CNM-Au8

30 mg of CNM-Au8

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Participants must have completed study CNMAu8.201.
• Able to understand and give written informed consent.

Exclusion Criteria

• Lack of treatment compliance during participation in the CNMAu8.201 (VISIONARY-MS) study.
• Positive pregnancy test.
• Any history of previous malignancy, with the exception of basal cell carcinoma of the skin or in situ carcinoma of the cervix, post documented full resections, with clean margins.
• Based on the Investigator's judgment, any concurrent chronic or acute illness or unstable medical condition that could confound the results of safety assessments, increase risk to the participant, or lead to difficulty complying with the protocol; any untreated or unstable psychiatric disease including depression, bipolar and psychosis.
• Participant is considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation.

Following clinical and serology sample analysis conducted at the end-of-study visit for CNMAu8.201 (VISIONARY-MS), participants may be removed from this long term extension study if any of the following criteria are met, at the discretion of the Medical Monitor and/or Sponsor's Medical Representative:

• Positive serology for viral hepatitis B and/or C and/or human immunodeficiency virus (HIV).
• Abnormal liver function tests (aspartate aminotransferase [ASAT] or alanine aminotransferase [ALAT] > 2x upper limit of normal range (ULN) or total bilirubin > 2x ULN or alkaline phosphatase (AP) > 3x ULN).
• Participants with clinically significant hepatic or renal dysfunction or clinical laboratory findings that would limit the interpretability of change in liver or kidney function (e.g., glomerular filtration rate < 40 mL/min [based on creatinine clearance according to Cockcroft-Gault equation]), or those with low platelet counts (<150 x 109 per liter) or eosinophilia (absolute eosinophil count of ≥500 eosinophils per microliter) at the EOS visit for CNMAu8.201 (Visionary-MS).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

George Clinical

UNKNOWN

Sponsor Role: collaborator

Clene Nanomedicine

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Sydney Brain Mind Centre

Camperdown, New South Wales, Australia

John Hunter Hospital

New Lambton Heights, New South Wales, Australia

Princess Alexandra Hospital

Woolloongabba, Queensland, Australia

Menzies Institute for Medical Research

Hobart, TAZ, Australia

The Alfred Centre Department of Neuroscience

Melbourne, Victoria, Australia

Countries

Canada; United States; Australia

Other Identifiers

CNMAu8.201LTE

Identifier Type: -

Identifier Source: org_study_id